IDIBELL and UB researchers, together with Mount Sinai, have described a group of microRNAs that would regulate Wnt/β-catenin signalling pathway-dependent breast cancers.
For the first time, one of the variants identified is unrelated to psychiatric disorders and would contribute through other factors such as smoking, insomnia, or the propensity to risk-taking.
Fluorizoline was known for its pro-apoptotic action on various tumor cells. Now, a study by IDIBELL and the University of Barcelona shows that apart from promoting cell death, this compound inhibits the degradation of mitochondria.
The ability to inhibit mitophagy converts fluorizoline into a promising antitumor agent Read More »
Dr. Mònica Povedano, principal investigator at IDIBELL and head of the Functional Unit for Motor Neuron Disease at the Bellvitge University Hospital, has been awarded the 2020 Neuromuscular Disease Prize (scientific modality), granted by the Spanish Society of Neurology (SEN).
Recognition of Dr. Mònica Povedano and the Functional Unit for Motor Neuron Disease work Read More »
The screening programs of cervical cancers diagnosticated by cervical cytologies have reduced the incidence and mortality of this cancer. However, a retrospective study of IDIBELL and ICO that included 371 women treated at the Hospital de Bellvitge has shown that these tests are not effective for endometrial cancer diagnosis.
Cervical cytologies are not sensitive enough to detect endometrial cancer Read More »
MCJ protein silencing emerges as a new therapy to prevent liver failure after ischaemia-reperfusion in models of metabolic syndrome and ageing.
A new study identified a possible biomarker for the appearance of cystine stones in the urinary tract in a murine model of cystinuria.
Identified a possible biomarker for the appearance of stones in cystinuria Read More »
The hematology team, from IDIBELL and ICO, has published an article in the journal Blood Advances that proposes this index as a tool to identify patients with higher risk to be transferred to the Intensive Care Unit (ICU) after hematopoietic stem cell transplant.
The results of a clinical trial, published in the New England Journal of Medicine, show that Tebentafusp is the first drug to increase overall survival in metastatic uveal melanoma, highly aggressive cancer that causes death in 50% of cases in less than a year.
According to the study, the higher mortality should be attributed to the advanced aged and the worst preoperative health.
